Gómez-Elias CL, Leyva-Macías LB

Language: Spanish
References: 14
Page: 99-103
PDF size: 496.37 Kb.

ABSTRACT

The implementation of the Highly Active Antiretroviral Therapy (HAART) has decreased the progression of the disease increasing the life expectancy in HIV pediatric patients, but at the same time, it raised the morbidity associated with this therapy. The complications involved are dyslipidemia, insulin resistance, osteopenia among others. Particularly, it has been proven that the protease inhibitors (PI) are significant risk factors for the development of hypercholesterolemia. In prospective cohort studies, it has been found that high viral load is considered a protector factor for the metabolic alterations on patients under a HAART, showing an inadequate adherence to the medical treatment. Therefore, despite the success in the viral management in children with HAART, the consequences of this therapy remain as a serious health problem for the long-term metabolic disorders.

REFERENCES

1. Tebas P, Powderly W et al. Accelerated bone mineral loss in HIV-infected patients receiving potent amtiretroviral therapy. AIDS; 2000, 14:F63-F67

2. Calza L, Manfredi R, Chiodo F. Use of Fibrates in the Management of Hyperlipidemia in HIV-Infected Patients Receiving HAART. Infection; 30(1):26-31.

3. Tassiopoulos, Katherine DS et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. JAIDS Journal of Acquired Immune Deficiency Syndromes; 2008,47(5):607-614.

4. MCComset G, Leonard E. Metabolic complications of HIV therapy in children. AIDS; 2004, 18:1753-1768

5. Taylor P. , Worrell C., Steinberg S. M., Hazra R., Jankelevich S., Wood L. V. et al. Natural history of lipid abnormalities and fat redistribution among Human Immunodeficiency Virus-infected children receiving long-term, protease inhibitor-containing highly active antiretroviral therapy regiments. Pediatrics; 2004, 114:235-42.

6. Lainka E., Oezbek S., Falck M., Ndagijimana J. and Niehues T. Marked Dyslipidemia in Human Immunodeficiency Virus-infected children on protease inhibitor- containing antiretroviral therapy. Pediatrics; 2002, 110:e56.

7. 7.Koppel K., Bratt G., Eriksson M. and Sandström E., Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV1 infection. International Journal of STD & AIDS; 2000, 11: 451-455.

8. Pavía R. N., Muñoz H. M. R., Santos P. J. I. Redistribución de grasa y alteraciones metabólicas en niños y adolescentes infectados por VIH/SIDA con tratamiento antirretroviralmente altamente activo, Bol Med Hosp Infant Mex; 2009, 66:343 -349.

9. Núñez-Cuadros E., Mellado-Peña M. J., Rivera- Cuello M., Penim-Fernández M., Piñeiro-Pérez R., García-Hortelano M., et al. Toxicidad de fármacos antirretrovirales en niños infectados por el virus de la inmunodeficiencia humana. An Pediactr ; 2008, 68 (5): 425-31.

10. Vigano A., Zuccotti GV., Cerini C. et al. Lipodystrophy, insulin, resistance, and adiponectin concentration in HIV infected children and Adolescents. Curr HIV Res; 2011, 9.

11. Tukei VJ, Asiimwe A., Maganda A. et al. Safety and tolerability of antirretroviral therapy among HIV infected children and adolescent in Uganda. J Acquir Immune Defic Syndr; 2011,28.

12. Alves C., Oliveira A. C., Brites C., Lipodystrophic syndrome in children and adolescents infected with the Human Immunodeficiency Virus. BJID; 2008,12(4):342-348

13. Werner M. L. F., Pone M. V. da S., Fonseca V. M., Chaves C. R. M. de M. Lipodistrophy syndrome and cardiovascular pediatric risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy. J Pediatr (Rio J); 2010, 86(1):27-32.

14. Palella F., Baker R et al. Mortality in the highly active antiretroviral therapy era, changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr; 2006, 43:27-34.